These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
264 related articles for article (PubMed ID: 20814720)
41. A review of the potential role of nano-enabled drug delivery technologies in amyotrophic lateral sclerosis: lessons learned from other neurodegenerative disorders. Mazibuko Z; Choonara YE; Kumar P; Du Toit LC; Modi G; Naidoo D; Pillay V J Pharm Sci; 2015 Apr; 104(4):1213-29. PubMed ID: 25559087 [TBL] [Abstract][Full Text] [Related]
42. LHRH-targeted nanoparticles for cancer therapeutics. Minko T; Patil ML; Zhang M; Khandare JJ; Saad M; Chandna P; Taratula O Methods Mol Biol; 2010; 624():281-94. PubMed ID: 20217603 [TBL] [Abstract][Full Text] [Related]
43. Nanomedicines for the Treatment of CNS Diseases. Reynolds JL; Mahato RI J Neuroimmune Pharmacol; 2017 Mar; 12(1):1-5. PubMed ID: 28150132 [TBL] [Abstract][Full Text] [Related]
44. The Dartmouth Center for Cancer Nanotechnology Excellence: magnetic hyperthermia. Baker I; Fiering SN; Griswold KE; Hoopes PJ; Kekalo K; Ndong C; Paulsen K; Petryk AA; Pogue B; Shubitidze F; Weaver J Nanomedicine (Lond); 2015; 10(11):1685-92. PubMed ID: 26080693 [TBL] [Abstract][Full Text] [Related]
45. Second world conference on nanomedicine and drug delivery. Ninan N; Thomas S; George A; Sebastian M Ther Deliv; 2011 Jun; 2(6):711-5. PubMed ID: 22822503 [TBL] [Abstract][Full Text] [Related]
46. Nanomedicine for Treatment of Lung Cancer. Hussain S Adv Exp Med Biol; 2016; 890():137-47. PubMed ID: 26703803 [TBL] [Abstract][Full Text] [Related]
47. Advances and Implications in Nanotechnology for Lung Cancer Management. Sarkar S; Osama K; Jamal QMS; Kamal MA; Sayeed U; Khan MKA; Siddiqui MH; Akhtar S Curr Drug Metab; 2017; 18(1):30-38. PubMed ID: 27842486 [TBL] [Abstract][Full Text] [Related]
49. Inorganic nanoparticles in cancer therapy. Bhattacharyya S; Kudgus RA; Bhattacharya R; Mukherjee P Pharm Res; 2011 Feb; 28(2):237-59. PubMed ID: 21104301 [TBL] [Abstract][Full Text] [Related]
50. Glioblastoma chemotherapeutic agents used in the clinical setting and in clinical trials: Nanomedicine approaches to improve their efficacy. Aparicio-Blanco J; Sanz-Arriazu L; Lorenzoni R; Blanco-Prieto MJ Int J Pharm; 2020 May; 581():119283. PubMed ID: 32240807 [TBL] [Abstract][Full Text] [Related]
51. Brain cancer diagnosis and therapy with nanoplatforms. Koo YE; Reddy GR; Bhojani M; Schneider R; Philbert MA; Rehemtulla A; Ross BD; Kopelman R Adv Drug Deliv Rev; 2006 Dec; 58(14):1556-77. PubMed ID: 17107738 [TBL] [Abstract][Full Text] [Related]
52. Application of nanotechnology in cancer therapy and imaging. Wang X; Yang L; Chen ZG; Shin DM CA Cancer J Clin; 2008; 58(2):97-110. PubMed ID: 18227410 [TBL] [Abstract][Full Text] [Related]
53. Systemic Delivery of Anti-miRNA for Suppression of Triple Negative Breast Cancer Utilizing RNA Nanotechnology. Shu D; Li H; Shu Y; Xiong G; Carson WE; Haque F; Xu R; Guo P ACS Nano; 2015 Oct; 9(10):9731-40. PubMed ID: 26387848 [TBL] [Abstract][Full Text] [Related]
54. Advancements in nanotherapeutics for Alzheimer's disease: current perspectives. Harilal S; Jose J; Parambi DGT; Kumar R; Mathew GE; Uddin MS; Kim H; Mathew B J Pharm Pharmacol; 2019 Sep; 71(9):1370-1383. PubMed ID: 31304982 [TBL] [Abstract][Full Text] [Related]
55. NANOMEDICINE: will it offer possibilities to overcome multiple drug resistance in cancer? Friberg S; Nyström AM J Nanobiotechnology; 2016 Mar; 14():17. PubMed ID: 26955956 [TBL] [Abstract][Full Text] [Related]
56. Role of Nanobiotechnology in Drug Delivery. Jain KK Methods Mol Biol; 2020; 2059():55-73. PubMed ID: 31435915 [TBL] [Abstract][Full Text] [Related]
57. Nanotechnology and glaucoma: a review of the potential implications of glaucoma nanomedicine. Kim NJ; Harris A; Gerber A; Tobe LA; Amireskandari A; Huck A; Siesky B Br J Ophthalmol; 2014 Apr; 98(4):427-31. PubMed ID: 24246373 [TBL] [Abstract][Full Text] [Related]
58. Nanomedicine to overcome cancer multidrug resistance. Yang X; Yi C; Luo N; Gong C Curr Drug Metab; 2014; 15(6):632-49. PubMed ID: 25255871 [TBL] [Abstract][Full Text] [Related]
59. Mechanisms of cooperation in cancer nanomedicine: towards systems nanotechnology. Hauert S; Bhatia SN Trends Biotechnol; 2014 Sep; 32(9):448-55. PubMed ID: 25086728 [TBL] [Abstract][Full Text] [Related]
60. Chemistry and formulations for siRNA therapeutics. Gallas A; Alexander C; Davies MC; Puri S; Allen S Chem Soc Rev; 2013 Oct; 42(20):7983-97. PubMed ID: 23857524 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]